Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $3.12 million. The enterprise value is -$6.93 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 2.78 million shares outstanding. The number of shares has increased by 109.25% in one year.
| Current Share Class | 2.78M |
| Shares Outstanding | 2.78M |
| Shares Change (YoY) | +109.25% |
| Shares Change (QoQ) | +146.20% |
| Owned by Insiders (%) | 0.47% |
| Owned by Institutions (%) | 1.73% |
| Float | 2.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.15 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -87.31% and return on invested capital (ROIC) is -37.47%.
| Return on Equity (ROE) | -87.31% |
| Return on Assets (ROA) | -25.85% |
| Return on Invested Capital (ROIC) | -37.47% |
| Return on Capital Employed (ROCE) | -67.45% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.17M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.11% in the last 52 weeks. The beta is 1.16, so TOVX's price volatility has been higher than the market average.
| Beta (5Y) | 1.16 |
| 52-Week Price Change | -90.11% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 2.79 |
| Relative Strength Index (RSI) | 41.91 |
| Average Volume (20 Days) | 22,330 |
Short Selling Information
The latest short interest is 70,210, so 2.52% of the outstanding shares have been sold short.
| Short Interest | 70,210 |
| Short Previous Month | 167,482 |
| Short % of Shares Out | 2.52% |
| Short % of Float | 2.93% |
| Short Ratio (days to cover) | 2.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.73M |
| Pretax Income | -20.35M |
| Net Income | -25.65M |
| EBITDA | -18.59M |
| EBIT | -18.73M |
| Earnings Per Share (EPS) | -$19.03 |
Full Income StatementBalance Sheet
The company has $11.61 million in cash and $1.57 million in debt, giving a net cash position of $10.04 million or $3.61 per share.
| Cash & Cash Equivalents | 11.61M |
| Total Debt | 1.57M |
| Net Cash | 10.04M |
| Net Cash Per Share | $3.61 |
| Equity (Book Value) | 19.07M |
| Book Value Per Share | 6.85 |
| Working Capital | 8.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.94 million and capital expenditures -$1,000, giving a free cash flow of -$16.94 million.
| Operating Cash Flow | -16.94M |
| Capital Expenditures | -1,000 |
| Free Cash Flow | -16.94M |
| FCF Per Share | -$6.09 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |